IMA is loading

How to minimize heating formation for an ibuprofen blend.

Authors
Federica Giatti, Compression Technologist at IMA Active
Fabriano Ferrini, Product Manager for tablet presses at IMA Active


1. Introduction

The challenge for tablet press producers is to design machines that can be at the same time cost/price effective for those customers producing standard product and highly customizable for special application. A change at design concept of these commodities machine is mandatory to be able to answer properly to these market requests. If it is true that exists a wide range of easy-tomanufacture products that permits to justify this expectation, there is a significant area of product’s recipe that are not optimized for industrial mass production, i.e. old formulation that have to satisfy current level of quality. There are also products with very restrictive physical properties that require specific customization on standard machine to be machinable, i.d thermosensitive products. This case study has the aim to verify the manufacturability of a Ibuprofen-based formulation, a well-known thermosensitive product while ensuring high output on an industrial double-side rotary tablet press.
The focus was the ability to reduce heating formation by the insertion of an air treatment unit (ATU) and process optimization.

 



 

2. Material and methods

Prexima 800 was assembled with Euro-D turret hosting 53 stations with Euro-D Ø 9 mm round biconvex punches.
Standard configurations was chosen in terms of feeding system and upper punch penetration. The test was conducted by simulating a standard production and measuring temperature in different equipment position over the time. Blend used were first a placebo, lactose and microcrystalline cellulose based, and secondly a real ibuprofen powder. 4 hours of continuous production have been performed: at the end the temperature decreasing was measured to verify technological choices and heat control.

 

3. Results

Prexima 800 rotated all night long in order to reach the mechanical inner overwarming as expected during a real production process of 3 shift. Afterwards, the machine was producing for 4 hours tablets rotating at controlled ambient temperature condition of 19°. Temperatures were monitored in different equipment positions at the beginning, after 1 hour, after 2 hours, after 3 hours and at the end (almost 4 hours and 30 minutes) as reported in Table 1.

 

Equipment position Temperature (°C)
Placebo

Ibuprofen

  Start 1h 2h 3h end Start 1h 2h 3h end
Room conditions  18.3 18.6 18.6 18.7 18.6 19 19 19 19 19
Machine table 27 31.6 31.3 32.2 34 20.9 21.7 20.7 20.9 22.2
Die Plate 28.2 33.6 33.5 34 38.9 21,1 23 24.9 25.1 25.1
Punches 26.3 26.5 29.5 30 37.7 21 24.2 26.1 26.5 27
Upper part of a turret 28.1 32.1 34.45 34.5 35.6 21.2 23.7 26.5 na 25.2
Lower part of a turret 29.15 33.6 35.45 35.5 39.06 21.7 23.7 26.5 na 25.2
Product 20.6 21.1  20.7 21.7 21 18.5 17.7 17.7 17.2 17.5
Tablets na 42.96 43.3 44.5 45 na 21.7 22 22.3 25

Table 1: temperatures monitored for placebo and ibuprofen trials.

 

The results were extremely interesting. The machine table that divides the mechanical area from the production area is the coolest part of the system, so that is possible to argue that the major part of the heat is not coming from the mechanical area. This result was expected because Prexima tablet presses use high efficiency gearbox and motor, as IMA technical choice.

Cooling systems are usually not part of a tablet press machine but are additional utilities that can be inserted in a standard layout.
The process area presents, on the top of the machine, inlet/outlet ports that can be used for an Air Treatment Unit, which controls the inlet temperature of the treated air in the process area, in order to obtain the required process temperature. The already proven solution allows to produce continuously tablets of an Ibuprofen-based formulation: target was to maintain always the temperature below 30°C by maximizing machine output.

The final solution was using the 3 inlet point from the top in the process area and additionally also the lower inlet point. To cool down the process area at 8-20°C, the calculated flow rate was 1000 m3/h at 14°C and relative humidity between 30-50%.

Repeating the same working condition of the preliminary placebo test to have comparative results, it was possible to reduce temperature (Table 1).

It is possible to extract the reduction (ΔT) between the temperature obtained during preliminary trials and with ibuprofen cooled-ATU application (Table 2):

 

Equipment position

ΔT (C)

Machine table -10.3
Die plate -13.8
Punches -10.7
Upper part of turret -10.4
Lower part of turret -13
Product -3.5
Tablets -20

Table 2: temperature gain with ATU application.

 

Die table and tablets, measured fully operational, have reached the same temperature, confirming that the main heat source is given by the tablet formation process.

The higher temperature achieved by the punches with respect to the other parts is mainly due the friction during their movement. Heat generated during the production for friction is proportional to the rotation speed of the machine, therefore, for a given fix speed, also the temperature increases up to a limited temperature, that remains under the 30°C.


 

4. Conclusion

The pro-active design of Prexima has permitted an easy implementation of an air treatment unit with no impact on the machine design and no additional cost for the customer. The cost were related directly to the ATU, confirming that flexibility is a design pillar that characterizes Prexima tablet presses and that has to be implemented in the machine concept. The payoff of such a strategy is not only the possibility to satisfy the customer’s need when required, but also to permit the implementation of a wide range of customization with cost related only to the additional optional required.

 

References

[1] https://www.pharmaworldmagazine.com/global-oral-solid-dosage pharmaformulation-market-projections/.
[2] https://drug-dev.com/growth-foreseen-at-all-levels-of-the-oral-solid-dosage-formexcipients-market/.

[3] Technology transfer and process optimization for a ibuprofen based formulation, “Process Worldwide”, November 2020.